Immediate zoledronic acid treatment better than delayed in women receiving letrozole
the ONA take:
Immediate treatment with zoledronic acid prevented bone loss compared with delayed treatment in postmenopausal women receiving letrozole for breast cancer and these differences were maintained at 5 years, a study published in the American Cancer Society journal Cancer has found.
Because it is known that postmenopausal women with breast cancer receiving aromatase inhibitors are at a higher risk for bone loss, researchers sought to compare the impact of immediate versus delayed treatment with zoledronic acid on bone loss.
Researchers analyzed data from 551 postmenopausal women who had received tamoxifen and were now receiving daily letrozole. Patients were randomly assigned 1:1 to upfront or delayed zoledronic acid 4mg IV every 6 months.
Results showed that the incidence of a 5% decrease in the total lumbar spine bone density was 10.2% and 41.2% in the upfront and delayed groups, respectively (P < 0.0001), suggesting that immediate treatment prevented bone loss moreso than delayed treatment at 5 years; however, researchers found that the incidence of osteoporosis or fractures was not significantly different between treatment arms.
Immediate treatment with zoledronic acid prevented bone loss compared with delayed treatment in breast cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|